Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups a, c, y and w-135) oligosaccharide diphtheria crm197 conjugate vaccine (Chiron Corporation)
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Menveo (MenACWY-CRM) is a quadrivalent meningococcal conjugate vaccine designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y. The vaccine consists of the capsular polysaccharides of these four serogroups, each individually conjugated to a non-toxic mutant diphtheria toxin carrier protein, CRM197. Originally developed by Chiron (later acquired by Novartis Vaccines, whose vaccine business was subsequently acquired by GSK), Menveo stimulates the production of bactericidal antibodies against the targeted serogroups. It was first approved by the FDA in 2010 for individuals aged 11 to 55 years, with subsequent label expansions down to infants as young as 2 months of age.
- Brand names
- Menveo
- Other names
- MenACWY-CRMNovartis Meningococcal (MenACWY) Conjugate VaccineNovartis Meningococcal (MenACWY-CRM) vaccinemeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccinemeningococcal A, C, W-135 and Y conjugate vaccinemeningococcal conjugate vaccinemeningococcal vaccine A,C,Y,W-135,diphtheria toxoid conj/PFquadrivalent meningococcal glycoconjugate vaccine
02
Targets
Complement (Complement system)MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on meningococcal (groups a, c, y and w-135) oligosaccharide diphtheria crm197 conjugate vaccine (Chiron Corporation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups a, c, y and w-135) oligosaccharide diphtheria crm197 conjugate vaccine (Chiron Corporation).